Antiviral Drugs Market against Novel Diseases Surges in 2024

By Shubhendra Anand , 05 April, 2025

Antiviral drugs are expanding their market size in 2024. The demand for antiviral drug production will increase in 2024 due to the increasing rate of prevailing diseases. Globally, the growth rate of viral diseases is a driving factor in the pharmaceutical market. Further, consumer demand for antiviral drugs with fewer side effects is evolving in the pharmaceutical sector.

Surveys of 2024 report that globally, the antiviral drugs segment may reach USD 51.18 billion in 2024. Moreover, the global revenue may turn around USD 55.3 billion from 2024 to 2029. The antiviral drug market is anticipated to grow with an annual growth rate of 1.58 percent. The antiviral drugs market expects the highest revenue in the United States in 2024. Consumers have been looking for variations in antiviral drugs for the last two years. The antiviral drugs segment has experienced significant growth over the years. It is driven mainly toward the treatment of novel epidemics like COVID-19. Further, consumers seek antiviral drugs with minimal side effects for better consumption.

The global market for antiviral treatments is forecasted to grow substantially, bolstered mainly by Biktarvy, an anti-HIV medication released by Gilead in 2018. The drug maintained high revenues throughout the forecast period. These treatments will likely be making an annual revenue of USD55 billion by 2029, an 8 percent increase from the projected revenue in 2024. Approval has been granted for ORLADEYO (berotralstat) as prophylaxis for patients with hereditary angioedema (HAE). This dosage form is administered orally with a frequency of once a day and is approved for use in adult and pediatric patients aged twelve years and older. Moreover, the antiviral drug Paxlovid developed by Pfizer yielded good revenue in 2022 and 2023. Hence, the antiviral drugs market for novel epidemics is anticipated to grow in the upcoming years.